Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4

Plain-language summary

This study examines circulating tumor markers in the blood, through blood samples and biopsy, in patients being treated for cancer. It enrolls patients aged 18 and older who are receiving cancer treatment at one of the participating centers. This non-phase study is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Recruiting

Sponsor

Institut Curie

Intervention

Blood sample, Biopsy

Start date

5/19/2022

Estimated completion

6/1/2031

Countries

France

Related genes

Locations

• Paris, France
• Saint-Cloud, France

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Patient treated for cancer at one of the participating center
* 18 years old or higher
* Signed informed consent form
* Patient not deprived of their liberty or under guardianship (including temporary guardianship)
* Patient covered by social security scheme
* Patient with no compliance issue (related to geographical, social or psychological reasons) for study follow up
* Other additional criteria will be defined (defining tumor type and clinical setting), by cohort

If a biopsy tumor sample is to be taken:

* Tumor considered as accessible by biopsy (at the investigator's discretion).
* Normal blood coagulation tests (if applicable, and in case of a non-superficial tumor lesion).
* No anticoagulant or antiaggregant treatment for the biopsy.

Exclusion Criteria :

Pregnant and/or breast-feeding women depending on cohort.